Table 1 Distribution of study participants, overall and by SARS-CoV-2 exposure history.

From: Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history

  Overall PCR +  Seropositive Seronegative
N 27 4 9 14
Age (years)
21–30
31–40
41–50
 > 50
N
10
6
5
6
N
0
1
2
1
N
7
1
1
0
N
3
4
2
5
Gender
Female
Male
N
14
13
N
3
1
N
4
5
N
7
7
Vaccine type
Moderna
Pfizer
N
11
16
N
3
1
N
2
7
N
6
8
Timing of blood sampling
Dose 1 (days after first dose)
Dose 2 (days after second dose)
Follow up (days after first dose)
Mean (range)
18.5 (11–23)
19.8 (8–26)
95.5 (70–124)
Mean (range)
14.3 (11–20)
19a
81.0 (70–102)
Mean (range)
19.2 (16–23)
20.0 (8–26)
94.8 (79–124)
Mean (range)
19.3 (17–21)
19.7 (14–26)
100.1 (88–120)
  1. aThree PCR + participants were not vaccinated with dose 2.